Clinical trial • Phase IV • Psychiatry

CANNABIDIOL for Post-traumatic stress disorder | Anxiety disorders

Phase IV trial of CANNABIDIOL for Post-traumatic stress disorder | Anxiety disorders. Placebo (Softisan 378); dose/schedule not specified-controlled.

Overview

Trial Therapeutic Area
Psychiatry
Trial Disease
Post-traumatic stress disorder | Anxiety disorders
Trial Stage
Phase IV
Drug Modality
Small molecule | Other

Key dates

Initial CTIS Submission Date
07-10-2024
First CTIS Authorization Date
29-10-2024

Trial design

Placebo (Softisan 378); dose/schedule not specified-controlled Phase IV trial in Netherlands.

Comparator
Placebo (Softisan 378); dose/schedule not specified
Target Sample Size
82
Trial Duration For Participant
14

Eligibility

Recruits 82 No vulnerable populations selected (isVulnerablePopulationSelected: false). Participants are adults (Age between 18-65). Specific consent/assent handling details not specified in the provided data..

Pregnancy Exclusion
For women: pregnant, a wish to become pregnant, or nursing
Vulnerable Population
No vulnerable populations selected (isVulnerablePopulationSelected: false). Participants are adults (Age between 18-65). Specific consent/assent handling details not specified in the provided data.

Inclusion criteria

  • {"criterion_text":"- Dutch uniformed personnel, which are (former) police-officers, firefighters, ambulance paramedics, military personnel or veterans.\n- Age between 18-65\n- Waiting for therapy for the treatment of a trauma and stressor-related and/or an anxiety disorder (as determined by the MINI PLUS psychiatric interview)"}

Exclusion criteria

  • {"criterion_text":"- Severe co-morbidity (severe major depressive or bipolar disorder and/or psychosis)\n- Alcohol and/or drug dependence\n- Inability to adequately read or speak Dutch\n- (a history of) epilepsy or brain damage, cardiac, renal or liver abnormalities\n- (a history of) allergies to medication (adverse reactions or rash)\n- Individuals taking certain medications known to have potential interactions with CBD (i.e., steroids, HMG-CoA reductase inhibitors, calcium channel blockers, antihistamines, antivirals, immune modulators, benzodiazepines, anti-arrhythmic, antibiotics, anesthetics, antipsychotics, antidepressants, anti-epileptics, beta blockers, proton pump inhibitors, NSAIDs, angiotensin II blockers, oral hypoglycemic agents, and sulfonylureas)\n- Used cannabis, synthetic cannabinoid, cannabinoid analogue, or any CBD or THC-containing product within 30 days of eligibility screening.\n- Individuals that had been diagnosed with intestinal, liver, or renal diseases that would affect absorption or clearance of CBD\n- For women: pregnant, a wish to become pregnant, or nursing"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Beck’s anxiety index between the first and second week.","definition_or_measurement_approach":"Not specified in the available data."}

Secondary endpoints

  • {"endpoint_text":"- Effect of CBD on Fear extinction (i.e. physiological responses and subjective fear)","definition_or_measurement_approach":"Physiological responses and subjective fear (as stated in the endpoint)"}
  • {"endpoint_text":"- Effect of CBD on stress regulation with the Maastricht Acute Stress Test (MAST; i.e. Subjective stress, physiological responses, alpha-amylase and cortisol)","definition_or_measurement_approach":"Measured with the Maastricht Acute Stress Test (MAST): subjective stress, physiological responses, alpha-amylase and cortisol (as stated)"}
  • {"endpoint_text":"- Effect of CBD on Sleep quality (i.e. questionnaires and a sleep watch)","definition_or_measurement_approach":"Measured by questionnaires and a sleep watch (as stated)"}

Recruitment

Planned Sample Size
82
Recruitment Window Months
18
Consent Approach
Participant informed consent is required (adult participants aged 18-65). A Subject Information Sheet and Informed Consent Form document is listed (L1_SIS and ICF), but specific details on who provides consent, age-specific documents, assent, or languages are not provided; exclusion criteria indicate inability to read or speak Dutch is exclusion, implying study materials are in Dutch.

Geography

Total Number Of Sites
1
Total Number Of Participants
82

Netherlands

Earliest CTIS Part Ii Submission Date
22-10-2024
Latest Decision Or Authorization Date
29-10-2024
Processing Time Days
7
Number Of Sites
1
Number Of Participants
82

Sites

Site Name
Universitair Medisch Centrum Utrecht
Department Name
Brain
Contact Person Name
Antoin de Weijer
Contact Person Email
A.d.DeWeijer@umcutrecht.nl

Sponsor

Primary sponsor

Full Name
Universitair Medisch Centrum Utrecht
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Netherlands

Third parties

  • {"country":"","full_name":"Brain Research and Innovation Center, Ministry of Defense","duties_or_roles":"Source of monetary support","organisation_type":""}

Investigational products

Investigational Product Name
Cannabidiol
Active Substance
CANNABIDIOL
Modality
Small molecule
Routes Of Administration
ORAL
Route
ORAL
Authorisation Status
Authorised (prodAuthStatus: 1)
Maximum Dose
600 mg per day
Investigational Product Name
Softisan 378
Modality
Other

Related trials

Other published trials that may interest you.